Pharmaceuticals News and Research

RSS

Quintiles agrees to acquire Encore Health Resources

As part of its continued efforts to strengthen and expand its service capabilities across the healthcare continuum, Quintiles today announced that it has signed an agreement to acquire Encore Health Resources.

12 May 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.

12 May 2014

Aratana initiates pivotal field effectiveness study for AT-001

Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis.

12 May 2014

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

12 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Researcher receives $3.3 million grant from NIH to find way for curing HIV

A George Mason University researcher has won a $3.3 million grant from the National Institutes of Health (NIH) that may lead to a way for curing HIV in the next five years.

12 May 2014

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto.

12 May 2014

Grace introduces ProVance Pre-packed Protein A Columns for mAb purification

W. R. Grace & Co. has introduced ProVance Pre-packed Protein A Columns, for purification of biologic drugs, specifically monoclonal antibodies (mAbs). Monoclonal antibodies represent the single largest biologics therapeutic category in the clinical development pipeline.

9 May 2014

Three NSU professors secure patents for their innovations

Three Nova Southeastern University's (NSU) professors from three different colleges recently secured patents for their innovations.

9 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Teaching people to self-manage diabetes leads to better results

Teaching people with diabetes how to control their blood glucose levels helps them achieve better results, finds a new study in Ethnicity and Disease. Surprisingly, providing intensive training to physicians of diabetes patients did not help patients achieve blood glucose control.

9 May 2014

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers.

9 May 2014

Drugmakers realign to reduce costs

Meanwhile, their trade group warns that the patient cost-sharing requirements in some health law plans could restrict prescription drug access.

9 May 2014

Cegedim and StratX collaborate to provide innovative, Life Sciences-specific training to employees

Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.

9 May 2014

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.

9 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

ApolloMed's revenues grow 35% to $10.5 million in fiscal 2014

Apollo Medical Holdings, Inc., an integrated, physician-centric healthcare delivery company, today announced financial results for the 12 months ended January 31, 2014.

9 May 2014

ImaginAb announces completion of $21M Series B financing

ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced today the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest.

9 May 2014